Is Phosphorus P 32 safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Phosphorus P 32. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Information in this record refers to the use of phosphorus P 32 as a therapeutic agent. No information is available on the use of phosphorus P 32 during breastfeeding. Use of phosphate P 32 as a skin patch to treat skin cancers poses no risk to breastfed infants after removal of the patch from the mother's skin
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Phosphorus P 32 decays by beta emission with an energy of 1.709 MeV and a half-life of 14.3 days.[1]
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Phosphorus P 32” (LM1148). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.